PM3 Win Buried Under Profit Collapse—Proof Required in H2
KUANTUM commissioned its modernized PM3 facility on schedule with 15-17% cost reductions achieved, yet Q2 profit collapsed 61% YoY to ₹2.2 Cr. Management has implicitly cut FY27 EBITDA margin guidance from 16-18% to 14%, and any recovery now depends entirely on unproven 7-11% price hikes (only 4% taken to date). Operational excellence has failed to translate to financial recovery.
₹279.1 Cr
flat YoY, down 8.1% QoQ
₹2.2 Cr
down 61% YoY; margin 0.8%
12.4%
reported; PM3 shutdown ₹40 Cr impact
₹9 Cr
1.5% margin on ₹533 Cr revenue
KUANTUM's Q2 profit has collapsed to ₹2.2 crore—a 61% decline year-on-year—despite successfully commissioning its modernized PM3 facility on schedule with tangible cost reductions in place. The quarter is distorted by the PM3 shutdown between 29 June and 21 August (₹40 crore EBITDA impact, 6,300 tons lost production), but even adjusting for that non-recurrence, the underlying 12.3% operating margin is critically weak for a company that guided to 16-18% EBITDA a year ago. Management has now implicitly cut FY27 margin guidance to 14%—a 200-400 basis point miss—and is betting entirely on H2 price hikes of 7-11% to recover, despite having taken only 4% so far. This is not a good quarter obscured by timing. It is a genuinely weak quarter with a genuine operational win trapped inside it.
The margin guidance cut (buried in Q&A, material in impact)
When asked about full-year margin guidance during Q&A, Pushkar Jain and Pavan Khaitan stated: 'Our margin target will be like 14% for this year and hopefully 17, 18 for the second half.' That 14% for full FY27 is a material downgrade from prior 16-18% guidance—not acknowledged upfront, but explicitly stated. H1 EBITDA delivery was 14% (₹75 Cr ÷ ₹533 Cr), so full-year 14% implies zero margin expansion in H2 despite anticipated 7-11% price hikes. The message is unambiguous: cost inflation has proven more stubborn than the capex thesis anticipated, and operational leverage is not materializing as promised. The 17-18% margin cited for 'the second half' appears to refer to FY28 H1, not H2 FY27—a critical distinction that management left vague.
What changed from prior calls
Prior guidance was anchored to a capex story: 'FY27 revenue ₹1,300 Cr+, EBITDA margin 16–18% by year-end.' The thesis was clean—modernized capacity online, cost reduction, margin expansion. Q2 upends it. The company delivered: PM3 in 59 days vs 65-day plan, cost reduction 15-17% on agro and wood inputs confirmed, capacity 675 tpd live. But profit has not expanded; it has collapsed. The narrative has reset entirely: now dependent on immediate price hike realization (7-11% in H2) to offset unabated input cost inflation. Only 4% realized; the remaining 3-7% is unproven and faces competitive headwinds. Additionally, management introduced a strategic pivot (new, not prior): specialty paper mix from 17-18% to 25-30% within 12-15 months, with PFAS-free grease-proof papers launching in Q3. This is a credible long-term margin lever, but it signals that near-term recovery is no longer expected from capex alone.
The bull case vs. the bear case
PM3 commissioned ahead of plan in 59 days
Cost reduction 15-17% on core inputs (DDS, steam optimization)
Revenue tracking ₹1,300 Cr FY27 target; H1 ₹533 Cr = 41% of run-rate
Debt peaking at ₹700 Cr, within ₹760-770 Cr guidance; deleveraging plan credible
Q2 PAT collapsed to ₹2.2 Cr (0.8% margin), down 61% YoY
H1 PAT (₹9 Cr, 1.5% margin) vs prior 16-18% EBITDA target—massive miss
EBITDA margin guidance implicitly cut 16-18% → 14% (material downgrade)
Price realization (4%) lags target (7-11%); competitive pressure rising
Lower-GSM demand forcing optimization at 600 tpd vs 675 tpd capacity
Specialty paper expansion (25-30% target in 12-15 months) unproven at scale
Risks ranked by concern to a holder
Price hike execution (7-11% target unproven; 4% realized)
HighOnly 4% price realization to date vs 7-11% needed for margin stabilization. Competitive dynamics and lower-GSM mix shift limit pricing power. If H2 realizes only 4-5%, margin stays at 12-14%, FY28 guidance (18-20%) becomes unrealistic, stock re-rates lower.
Debt leverage and interest coverage
HighPeak debt ₹700 Cr with 3-3.5% annual interest+depreciation impact. If FY27-28 margin recovery stalls (stays at 12-14% vs 16%+ target), interest coverage erodes. Debt reduction (₹170-180 Cr annually) is contingent on FCF generation; if earnings disappoint, deleveraging slips and leverage becomes stressed.
Lower-GSM demand capping capacity ROI
MediumPM3 increased capacity to 675 tpd, but market is trending lower GSMs (52-58 vs 64-70 historical). Company optimizing at 600 tpd, capping volume upside. Specialty paper ramp (25-30% target) is intended mitigation, but unproven. Capex payoff is contingent on product mix success.
Specialty paper transition execution
MediumTarget 25-30% specialty mix in 12-15 months; PFAS-free grease-proof paper launched Q3. If customer adoption lags or pricing doesn't support margin uplift, specialty transition delays and margin recovery is pushed into FY28 or beyond.
Input cost inflation persistence
MediumWest Asia war, coal supply diversion to power sector, global freight volatility ongoing. Management expects normalization by Q3-Q4, but visibility is low. If inflation persists, 7-11% price hikes will be insufficient offset, and margins remain structurally depressed.
FY27 revenue target execution (₹1,300 Cr+)
Low-MediumH1 ₹533 Cr is 41% of target; H2 needs strong execution. Q2 QoQ momentum was negative (-8.1%), but PM3 ramp and seasonal improvement in H2 may support. Moderate execution risk, not critical to the story.
How the street is positioned
The market has rendered its verdict with brutal clarity. The stock trades at ₹64.6, down from a 52-week high of ₹111.3 and -70.65% from its all-time high of ₹220.13. It sits below its 20-day (₹71.7), 50-day (₹74.26), and 200-day (₹79.2) simple moving averages—a consistent bearish structure with no near-term support. Institutional interest is negligible and shrinking: FII at 0.04%, DII at 0.01%, essentially zero. Promoters hold 70.30% steady, unchanged quarter after quarter—no insider buying, no block deals, no vote of confidence. Volume is normal (no panic selling but no capitulation either). The market's message is unambiguous: Kuantum is a low-confidence, high-leverage restructuring story, and the Q2 result has reinforced that skepticism. The stock's 70% drawdown from ATH is not a capitulation bottom; it is a repricing of risk. A recovery would require concrete evidence of price realization in H2 and a reset of management credibility after the implicit margin guidance miss.
What to watch next
1 · H2 price realization (target 7-11%, current 4%)
This is the critical lever. If management achieves 7-11% in H2, EBITDA margin could stabilize around 15-16%, supporting the 14% full-year guidance. If realization stays at 4-5%, margin compresses further and the recovery thesis collapses. Watch quarterly pricing in next result.
2 · Q3 FY27 profit (Oct-Dec 2026) ex-shutdown distortion
Q2 is artificially depressed by the ₹40 Cr EBITDA shutdown impact. Q3 will show if that was the problem (Q3 normalized PAT 8-10% margin = thesis intact) or if base-case profit is genuinely weak (Q3 PAT under 5% margin = thesis broken). This quarter resolves the transitory vs structural debate.
3 · Specialty paper portfolio adoption (target 25-30% in 12-15 months)
PFAS-free oil & grease-resistant papers launched in Q3. Monitor segment revenue, order book, and pricing in next results. If specialty mix expands to 20%+ with pricing support, margin uplift is credible. If stuck at 18%, the pivot is stalled and FY28 guidance is at risk.
4 · Government MIP decision on writing-printing segment (3-6 month timeline)
MIP (Modified Intended Prices subsidy) is in place for kraft/paperboard. Writing-printing MIP is under investigation. Approval would strengthen pricing power; delay/rejection would weaken near-term outlook and reduce government support argument.
Kuantum is operationally executing (PM3 on time, costs down 15-17%), but financially faltering (profit down 61%, margins implicitly cut). The quarter is not a rotation failure; it is a gap between headline capex wins and bottom-line delivery. The cost reduction is real, but input cost inflation has overwhelmed it. Pricing power is weak, and H2 recovery is entirely contingent on unproven price hikes (7-11% target, 4% realized). The market's 70% drawdown from ATH and minimal institutional ownership reflect deep skepticism of the turnaround narrative.
A hold is justified here. The operational story is real, but financial credibility has been dented by the implicit margin guidance cut (16-18% → 14%) and the profit collapse (0.8% Q2 margin). For conviction to rotate back to buy, management must demonstrate H2 price realization (7-11%) and a return to normalized profit margins (8%+ PAT margin, 15%+ EBITDA margin) in Q3. If H2 margins remain at 12-14%, the FY28 guidance to 18-20% EBITDA becomes aspirational, leverage risk surfaces, and the stock likely re-rates lower.
The single number to track from here: H2 EBITDA margin. If it reaches 16%+, the FY28 recovery thesis survives and upside emerges. If it stays at 12-14%, the guidance cycle has reset and downside becomes the base case. Price hikes, specialty mix, and debt reduction are all secondary to that number.
Informational and educational content only. Not investment advice.